Literature DB >> 7236892

Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.

R I Fisher, S M Hubbard, V T DeVita, C W Berard, R Wesley, J Cossman, R C Young.   

Abstract

Clinical and histopathologic material from 151 cases of diffuse mixed, diffuse histiocytic, and diffuse undifferentiated non-Burkitt's lymphomas have been reviewed to determine the factors that predict long-term survival. Median survival of all patients was 34 mo with 43% alive at 70 mo. Factors associated with a poor prognosis include: male sex, constitutional symptoms, advanced stage, bone marrow involvement, huge (greater than 10 cm) abdominal masses with gastrointestinal involvement, hepatic involvement, hemoglobin greater than 12 g/dl, or serum LDH greater than 250 U. The best prediction of a given patient's survival was defined by a set of four variables, which includes sex, symptoms, bone marrow status, and the presence or absence of a huge abdominal mass with gastrointestinal involvement. In contrast, classification of these patients according to the histopathologic categories of Rappaport of Strauchen did not define patient groups with significant differences in survival, nor did these categories correlate with the previously described clinical factors. Knowledge of the distribution of these prognostic factors in any clinical trial is needed before therapeutic results can be compared. In addition, such data may define subsets of patients for whom current therapy is inadequate and conversely those patients for whom current therapy yields excellent long-term survival.

Entities:  

Mesh:

Year:  1981        PMID: 7236892

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.

Authors:  Joseph A Sparano; Abdissa Negassa; Erick Lansigan; Robin Locke; Chamath R De Silva; Peter H Wiernik
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  [Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].

Authors:  B Steinke; J Mau
Journal:  Klin Wochenschr       Date:  1986-05-15

3.  MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.

Authors:  W Oster; T Forsthuber; H H Hennekeuser; H Gamm; A Lindemann; G Schmitz; H G Fuhr; R Hinterberger; H Kreiter; W Thoenes
Journal:  Blut       Date:  1990-01

Review 4.  Non-Hodgkin's lymphoma.

Authors:  S C Gulati; C Gulati; R Vega; L Gandola; J Yopp; R Dinsmore; R O'Reilly; B Clarkson
Journal:  Indian J Pediatr       Date:  1983 Nov-Dec       Impact factor: 1.967

Review 5.  Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.

Authors:  E G MacEwen
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

6.  Prognostic significance of biochemical markers in African Burkitt's lymphoma.

Authors:  F K N Arthur; L Owusu; F A Yeboah; T Rettig; A Osei-Akoto
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

Review 7.  Current approaches to the treatment of advanced-stage non-Hodgkin's lymphoma.

Authors:  J J Rusthoven
Journal:  CMAJ       Date:  1987-01-01       Impact factor: 8.262

8.  Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.

Authors:  R Heinz; H Hanak; A Stacher
Journal:  Klin Wochenschr       Date:  1985-07-15

9.  MACOP-B treatment in patients with Ki-1-positive large-cell anaplastic lymphoma.

Authors:  C Marosi; R Heinz; G Steger; A Fortelny; A Chott; H Hanak; T Radaszkiewicz; M Baur; G Kreiner; I Schwarzinger
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  CHOP-firstline treatment in NHL with unfavorable prognosis--evaluation of therapeutic response and factors influencing prognosis.

Authors:  R Heinz; E Neumann; P Aiginger; J Pont; J Schüller; G Walcher; H Hanak; T Radaszkiewicz; E Sinn; M Wirth
Journal:  Blut       Date:  1985-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.